Trinity Biotech plc (NASDAQ:TRIB) Sees Large Growth in Short Interest

Trinity Biotech plc (NASDAQ:TRIB) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 18,400 shares, a growth of 70.4% from the June 30th total of 10,800 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average daily volume of 52,400 shares, the short-interest ratio is presently 0.4 days.

Trinity Biotech Price Performance

NASDAQ TRIB traded down $0.11 on Friday, reaching $2.88. The stock had a trading volume of 10,558 shares, compared to its average volume of 67,522. The company has a market cap of $21.95 million, a P/E ratio of -1.03 and a beta of 1.31. The firm has a fifty day moving average of $2.34 and a two-hundred day moving average of $2.21. Trinity Biotech has a 1-year low of $1.49 and a 1-year high of $5.10.

Trinity Biotech (NASDAQ:TRIB) last posted its quarterly earnings data on Thursday, May 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter. The business had revenue of $14.70 million for the quarter. Research analysts predict that Trinity Biotech will post -2.17 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of Trinity Biotech in a research note on Sunday, July 21st. They issued a “buy” rating for the company.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.